BIO-RAD LABORATORIES, INC.BIOEarnings & Financial Report
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
Revenue
$638.5M
Gross Profit
$355.1M
Operating Profit
$101.5M
Net Profit
$-2.2B
Gross Margin
55.6%
Operating Margin
15.9%
Net Margin
-339.2%
YoY Growth
-6.3%
EPS
$-76.26
BIO-RAD LABORATORIES, INC. Q2 FY2024 Financial Summary
BIO-RAD LABORATORIES, INC. reported revenue of $638.5M (down 6.3% YoY) for Q2 FY2024, with a net profit of $-2.2B (down 86.3% YoY) (-339.2% margin). Cost of goods sold was $283.4M, operating expenses totaled $253.6M.
Key Financial Metrics
| Total Revenue | $638.5M |
|---|---|
| Net Profit | $-2.2B |
| Gross Margin | 55.6% |
| Operating Margin | 15.9% |
| Report Period | Q2 FY2024 |
Revenue Breakdown
BIO-RAD LABORATORIES, INC. Q2 FY2024 revenue of $638.5M breaks down across 2 segments, led by Clinical Diagnostics at $387.9M (60.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Clinical Diagnostics | $387.9M | 60.8% |
| Life Science | $250.5M | 39.2% |
BIO-RAD LABORATORIES, INC. Revenue by Segment — Quarterly Trend
BIO-RAD LABORATORIES, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Clinical Diagnostics and Life Science) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Clinical Diagnostics | $425.3M | $391.2M | $388.8M | $356.8M |
| Life Science | $267.9M | $261.8M | $262.8M | $228.6M |
BIO-RAD LABORATORIES, INC. Annual Revenue by Year
BIO-RAD LABORATORIES, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $2.6B).
| Year | Annual Revenue |
|---|---|
| 2025 | $2.6B |
| 2024 | $2.6B |
| 2023 | $2.7B |
| 2022 | $2.8B |
BIO-RAD LABORATORIES, INC. Quarterly Revenue & Net Profit History
BIO-RAD LABORATORIES, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $693.2M | +3.9% | $720.0M | 103.9% |
| Q3 FY2025 | $653.0M | +0.5% | $-341.9M | -52.4% |
| Q2 FY2025 | $651.6M | +2.1% | $317.8M | 48.8% |
| Q1 FY2025 | $585.4M | -4.2% | $64.0M | 10.9% |
| Q4 FY2024 | $667.5M | -2.0% | $-715.8M | -107.2% |
| Q3 FY2024 | $649.7M | +2.8% | $653.2M | 100.5% |
| Q2 FY2024 | $638.5M | -6.3% | $-2.2B | -339.2% |
| Q1 FY2024 | $610.8M | -9.8% | $383.9M | 62.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $610.8M | $638.5M | $649.7M | $667.5M | $585.4M | $651.6M | $653.0M | $693.2M |
| YoY Growth | -9.8% | -6.3% | 2.8% | -2.0% | -4.2% | 2.1% | 0.5% | 3.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $12.61B | $9.69B | $10.60B | $9.36B | $9.53B | $10.21B | $9.70B | $10.58B |
| Liabilities | $3.56B | $2.91B | $3.12B | $2.79B | $2.85B | $3.09B | $2.96B | $3.12B |
| Equity | $9.05B | $6.78B | $7.49B | $6.57B | $6.68B | $7.13B | $6.74B | $7.45B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $69.8M | $97.6M | $163.6M | $124.2M | $129.9M | $116.5M | $120.9M | $164.9M |